How did we get here
Softhale successfully completed its first surveillance audit for ISO 13485 –March 2022
invoX Pharma acquires Softhale N.V. –March 2021
On 22 March 2021, invoX Pharma Ltd, a research-driven global biopharmaceutical company, entered into an agreement to fully acquire Softhale N.V.
Successful series B fundraising –February 2019
Softhale’s proprietary device technology is protected by more than 15 patents. Our portfolio also expanded with a branded high-end product.
Internal team growth –December 2018
Throughout 2018 and 2019, we recruited leading industry experts in the respiratory field with a long track record of bringing inhaled branded and generic products to market.
Softhale’s first laboratory was opened –August 2017
Softhale moves into the office in Diepenbeek, Belgium –April 2017
Series A round completed –December 2016
Successfully raised more than €1 million in Series A funding and a initiated a first customer-funded proof-of-concept study.
Softhale N.V. was established in Diepenbeek, Belgium –February 2016
Early-stage proof-of-concept work –February 2015
Business plan creation –January 2014
After having conducted concept validation work and initial freedom-to-operate analysis, the team created the business plan that would help Softhale secure seed funding.
First patent was filed by the group –June 2013
Starting conceptual work on a new generation Soft Mist Inhaler (SMI) –January 2012
The founding members of Softhale started conceptual work on a new generation Soft Mist Inhaler (using proven expertise in microfluidic, medical device, pharmaceutical, and business development). Their collaboration resulted in the decision to start a pharmaceutical company.